Antiplatelet agents

This page covers all Antiplatelet agents drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting COX-1 (aspirin); P2Y12 receptor (thienopyridines), Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel), P2Y12 receptor.

Targets

COX-1 (aspirin); P2Y12 receptor (thienopyridines) · Cyclooxygenase (aspirin); P2Y12 receptor (clopidogrel) · P2Y12 receptor

Marketed (3)

• Aspirin or thienopyridine · Associations for Establishment of Evidence in Interventions · Cardiovascular
  Aspirin and thienopyridines inhibit platelet aggregation through different pathways to prevent blood clots and reduce cardiovascular events.
• placebo, aspirine, clopidogrel · University Hospital, Angers · Cardiovascular
  This is a combination study comparing placebo, aspirin (a non-selective cyclooxygenase inhibitor), and clopidogrel (a P2Y12 platelet receptor antagonist) for antiplatelet effects.
• Blinded clopidogrel · VA Office of Research and Development · Metabolic